Recent share performance and business profile

Regeneron Pharmaceuticals (REGN) has seen its stock decline around 2% over the past day and 2% over the past week, extending a fall of about 7% over the past month and 13% over the past 3 months.

Over longer periods, the stock shows a mixed picture, with a gain of about 18% over the past year, a decline of roughly 7% across 3 years, and an increase of about 39% over 5 years, while year to date it is down about 10%.

The company reports annual revenue of about US$14.9b and net income of roughly US$4.4b, with both revenue and net income showing positive annual growth based on the latest figures provided.

With the share price at about US$698.25 and the stock down over recent weeks and months, but with a positive 1 year total shareholder return, recent momentum looks softer than the longer term picture suggests.

If Regeneron’s recent pullback has you rethinking your exposure to healthcare and AI, it could be a good moment to scan the market for other focused opportunities with the 32 healthcare AI stocks

So with Regeneron’s shares easing back despite recent revenue and net income growth, and trading below some intrinsic and analyst value indicators, are you looking at a potential opportunity here, or has the market already priced in future growth?

Most Popular Narrative: 20.2% Undervalued

Regeneron’s most followed narrative pegs fair value at about $875.31 per share, compared with the last close at $698.25. This sets up a valuation gap built on detailed growth and margin assumptions.

Regeneron's broad and advancing pipeline including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronnextamab), genetic medicines, and obesity positions the company to benefit from demographic driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline driven earnings upside.

Curious what sits behind that projected step up in revenue, profit margins and future P/E multiple, and how it all feeds into that higher fair value?

Result: Fair Value of $875.31 (UNDERVALUED)

However, you also need to weigh ongoing EYLEA competition and pricing pressure, as well as policy and reimbursement risks that could cap returns even if the pipeline delivers.

Next Steps

If this mix of optimism and caution resonates with you, do not wait too long to review the underlying drivers and form your own stance. You can start with the 4 key rewards.

Looking for more investment ideas?

Do not stop your research with one healthcare stock. A wider watchlist built from high quality ideas can help you stress test your convictions and spot fresh opportunities.

• Zero in on potential value opportunities before the crowd notices by scanning 51 high quality undervalued stocks that combine quality traits with pricing that may look appealing.
• Strengthen the defensive side of your portfolio by sifting through 66 resilient stocks with low risk scores designed to highlight companies with more resilient profiles.
• Get ahead of the market's next talking points by reviewing the screener containing 21 high quality undiscovered gems that still sit off many investors' radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.